A Phase 4 interventional study of Gonadotropin Releasing Hormone Agonists (GNRH) and Androgen receptor (AR) inhibitor in Androgen Deprivation Therapy, Prostate Cancer and Hypertension, sponsored by Virginia Commonwealth University. Recruiting at 1 site in United States. Open to male participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Virginia Commonwealth University · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Prostatic Neoplasms by Virginia Commonwealth University — 4 open to participants now, 4 under way, none of them phase 3. Prostatic Neoplasms · Virginia Commonwealth University.
Among the 14 studies in Prostatic Neoplasms by Virginia Commonwealth University, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is the only one in phase 4, and was the 14th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →4 of the 14 studies in Prostatic Neoplasms by Virginia Commonwealth University are open now, in 1 country. Recruiting first, the newest first:
Virginia Commonwealth University · Sites in United States
Ages 18+ · Men only
Virginia Commonwealth University · Sites in United States
Ages 40–85 · Men only
Virginia Commonwealth University · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 40 Years and older · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 1 · Phase 4 1
First in 2007; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 28 across the 12 interventional studies, 73 across the 2 observational. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
Virginia Commonwealth University is the lead sponsor of 648 studies on the registry; 80 are open to participants now.
Of its 90 completed or terminated interventional studies of FDA-regulated products, 64 (71%) have results posted.
1 of the studies in Prostatic Neoplasms by Virginia Commonwealth University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06636123Virginia Commonwealth UniversityGZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Prostatic Neoplasms by Virginia Commonwealth University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (ADT) to treat prostate cancer. Prostate cancer is the most common non-skin cancer in men, affecting approximately 1 in 8 American men and its primary treatment is through the use of ADT. However, ADT increases the likelihood of developing heart disease including high blood pressure. This study will determine if dysfunction of the nervous system and/or kidneys occurs in men undergoing ADT, as these systems play a significant role in control of blood pressure. The results from this study will help us understand the ways in which ADT contributes to heart disease and help us develop therapies to prevent heart disease in prostate cancer survivors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Men undergoing androgen deprivation therapy via gonadotropin releasing hormone agonist plus androgen receptor inhibitor for the treatment of prostate cancer
Drug: Gonadotropin Releasing Hormone Agonists (GNRH) · Drug: Androgen receptor (AR) inhibitor
Healthy men undergoing gonadal suppression via gonadotropin releasing hormone agonist plus androgen receptor inhibitor for 9 weeks
Drug: Gonadotropin Releasing Hormone Agonists (GNRH) · Drug: Androgen receptor (AR) inhibitor
Healthy men undergoing placebo for 9 weeks.
Drug: Placebo
8 weeks of GnRH agonist
Also known as: Leuprolide
2 weeks of AR inhibitor
Also known as: Bicalutamide, Flutamide
Placebo tablet and injection
Change in cardiovagal baroreflex sensitivity
The change in cardiovagal baroreflex sensitivity will be assessed via the sequence method
Time frame: Before and after 9 weeks of ADT or placebo
Change in blood pressure reactivity to the cold pressor test
The change in systolic blood pressure will be assessed from quiet rest to sympathetic activation using the cold pressor test
Time frame: Before and after 9 weeks of androgen deprivation therapy or placebo
Change in exercise pressor reflex
The change in systolic blood pressure will be assessed from quiet rest to isometric handgrip exercise
Time frame: Before and after 9 weeks of androgen deprivation therapy or placebo
Change in ambulatory blood pressure variability
Ambulatory systolic blood pressure variability will be determined from 24-hour ambulatory blood pressure monitoring using the standard deviation of blood pressure readings
Time frame: Before and after 9 weeks of androgen deprivation therapy or placebo
Change in beat-to-beat blood pressure variability
Beat-to-beat systolic blood pressure variability will be determined using the standard deviation of blood pressure readings from finger photoplethysmography measured in the laboratory.
Time frame: Before and after 9 weeks of androgen deprivation therapy or placebo
Change in renal vascular resistance
Renal blood flow will be determined using ultrasound and blood pressure will be determined using finger photoplethysmography. These measures will be used to estimate renal vascular resistance.
Time frame: Before and after 9 weeks of androgen deprivation therapy or placebo
Change in kidney injury biomarkers
Neutrophil gelatinase-associated lipocalin (NGAL), tissue inhibitor of metalloproteinases 2 (TIMP2), and insulin-like growth factor binding protein 7 (IGFBP7) will be quantified in urine using commercially available assay kits. Concentrations will be normalized to urinary flow rate.
Time frame: Before and after 9 weeks of androgen deprivation therapy or placebo
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Jul 2028, 23 months after the start.
Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's planned 23 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gonadotropin-Releasing Hormone
Virginia Commonwealth University →